{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:28:29Z","timestamp":1791167309048,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,4]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Lenalidomide inhibits CLL proliferation in a cereblon\/p21-dependent manner. Treatment with lenalidomide induces p21 in CLL independent of p53.<\/jats:p>","DOI":"10.1182\/blood-2014-03-559591","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T08:00:50Z","timestamp":1404374450000},"page":"1637-1644","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":77,"title":["Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21WAF1\/Cip1-dependent mechanism independent of functional p53"],"prefix":"10.1182","volume":"124","author":[{"given":"Jessie-F.","family":"Fecteau","sequence":"first","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G.","family":"Corral","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela M.","family":"Ghia","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Gaidarova","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diahnn","family":"Futalan","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ila Sri","family":"Bharati","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cathers","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schwaederl\u00e9","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cui","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Lopez-Girona","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Structural Biology, Celgene Corporation, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davorka","family":"Messmer","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California, San Diego, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111817341309100_B1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"issue":"6","key":"2019111817341309100_B2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00001622-200211000-00008","article-title":"Thalidomide and immunomodulatory drugs as cancer therapy.","volume":"14","author":"Raje","year":"2002","journal-title":"Curr Opin Oncol"},{"issue":"16","key":"2019111817341309100_B3","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2004.05.984","article-title":"Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.","volume":"22","author":"Richardson","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2019111817341309100_B4","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","article-title":"Lenalidomide mode of action: linking bench and clinical findings.","volume":"24","author":"Davies","year":"2010","journal-title":"Blood Rev"},{"issue":"15","key":"2019111817341309100_B5","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.","volume":"26","author":"Andritsos","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111817341309100_B6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111817341309100_B7","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.","volume":"18","author":"Riches","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"13","key":"2019111817341309100_B8","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood-2012-08-447664","article-title":"Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.","volume":"121","author":"Schulz","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111817341309100_B9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2249.2002.01954.x","article-title":"Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.","volume":"130","author":"Marriott","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2019111817341309100_B10","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111817341309100_B11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111817341309100_B12","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111817341309100_B13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.","volume":"94","author":"Aue","year":"2009","journal-title":"Haematologica"},{"issue":"13","key":"2019111817341309100_B14","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111817341309100_B15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"2019111817341309100_B16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.","volume":"35","author":"Qian","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"2019111817341309100_B17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","article-title":"In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.","volume":"115","author":"Messmer","year":"2005","journal-title":"J Clin Invest"},{"key":"2019111817341309100_B18","first-page":"1163","article-title":"Chronic lymphocytic leukemia and related diseases.","volume-title":"Williams Hematology","author":"Kipps","year":"2001"},{"issue":"12","key":"2019111817341309100_B19","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood.V95.12.3853","article-title":"CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.","volume":"95","author":"Chu","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111817341309100_B20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0960-9822(99)80043-8","article-title":"Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells.","volume":"9","author":"Granelli-Piperno","year":"1999","journal-title":"Curr Biol"},{"issue":"6456","key":"2019111817341309100_B21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/366701a0","article-title":"p21 is a universal inhibitor of cyclin kinases.","volume":"366","author":"Xiong","year":"1993","journal-title":"Nature"},{"issue":"4","key":"2019111817341309100_B22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","article-title":"The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.","volume":"75","author":"Harper","year":"1993","journal-title":"Cell"},{"issue":"11","key":"2019111817341309100_B23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"2019111817341309100_B24","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111817341309100_B25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111817341309100_B26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"6168","key":"2019111817341309100_B27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"2019111817341309100_B28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"12","key":"2019111817341309100_B29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2019111817341309100_B30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01667.x","article-title":"Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.","volume":"87","author":"Arumainathan","year":"2011","journal-title":"Eur J Haematol"},{"issue":"21","key":"2019111817341309100_B31","article-title":"Trial of pulse dosed lenalidomide in previously treated chronic lymphocytic leukemia [abstract].","volume":"116","author":"Aue","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111817341309100_B32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10428190903406806","article-title":"Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.","volume":"51","author":"Sher","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2019111817341309100_B33","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"issue":"7","key":"2019111817341309100_B34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cellsig.2010.01.013","article-title":"Examination of the expanding pathways for the regulation of p21 expression and activity.","volume":"22","author":"Jung","year":"2010","journal-title":"Cell Signal"},{"issue":"5971","key":"2019111817341309100_B35","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity.","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"9-10","key":"2019111817341309100_B36","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","article-title":"The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity.","volume":"48","author":"John","year":"2011","journal-title":"Mol Immunol"},{"issue":"11","key":"2019111817341309100_B37","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1093\/emboj\/18.11.3090","article-title":"Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes.","volume":"18","author":"Koipally","year":"1999","journal-title":"EMBO J"},{"issue":"10","key":"2019111817341309100_B38","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-04-3995","article-title":"Lost in transcription: p21 repression, mechanisms, and consequences.","volume":"65","author":"Gartel","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"2019111817341309100_B39","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1038\/leu.2010.199","article-title":"A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL\/SLL.","volume":"24","author":"Brown","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"2019111817341309100_B40","article-title":"A combination of fludarabine\/rituximab with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): the REVLIRIT CLL5 AGMT Phase I\/II study, clinical and exploratory analyses of induction results [abstract].","volume":"118","author":"Egle","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111817341309100_B41","article-title":"Preliminary results from a phase I\/II study of fludarabine, rituximab, and lenalidomide in untreated patients with chronic lymphocytic leukemia (CLL) [abstract].","volume":"116","author":"Flinn","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts)"},{"issue":"5","key":"2019111817341309100_B42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2013-04-495341","article-title":"Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.","volume":"122","author":"Strati","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/10\/1637\/1379749\/1637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/10\/1637\/1379749\/1637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T23:35:06Z","timestamp":1689377706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/10\/1637\/32983\/Lenalidomide-inhibits-the-proliferation-of-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,4]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,9,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-03-559591","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,4]]}}}